UNSPSC 51295100: Antidepressants, synthesized

This classification denotes Antidepressants composed of multiple constituents, with no dominant constituent.

UNSPSC 51295100 Antidepressants, synthesized is a Class code, but the recent state and local opportunities tagged under it do not reflect antidepressant procurement — instead, they show demand for naloxone, general pharmaceutical supply through cooperative purchasing, and exploratory direct-to-manufacturer prescription programs. Seminole County, Florida solicited naloxone and drug deactivation systems through IFB; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and over-the-counter products across participating state and local facilities; and the Texas Health and Human Services Commission posted a Request for Information on therapeutic pharmacy initiatives. The code's nominal scope and the work actually being bought show little alignment, suggesting either a tagging error in the source data or that state and local governments are using this code to encompass a broader range of pharmaceutical procurement than antidepressants alone. The issuing bodies are a county health department, a multi-state cooperative purchasing vehicle, and a state health agency — a typical mix for pharmaceutical sourcing across state and local government.

Geographic activity centers on Florida, Texas, and Minnesota, with the MMCAP cooperative extending to Oregon. Seminole County's procurement (IFB 60459723LAS) required quarterly delivery of naloxone and drug deactivation systems to the county community health building, with a response deadline of July 26, 2023. MMCAP's RFP (S1070000015802), posted January 20, 2026, sought generic pharmaceuticals and OTC products from manufacturers willing to work through authorized wholesalers, with proposals due March 26, 2026, and awarded contracts effective July 1, 2026; evaluation weighted price competitiveness at 75 percent and required vendors to maintain $5 million commercial general liability and $2 million network security and professional liability coverage. The Texas HHS Commission's RFI (HHS0017013), posted April 3, 2026, explored vendor capacity for direct-to-manufacturer prescription programs without pharmacy benefit managers, functioning as a preliminary market-intelligence effort ahead of formal procurement.